Supraphysiological androgens suppress prostate cancer growth through androgen receptor-mediated DNA damage.

Prostate cancer (PC) is initially dependent on androgen receptor (AR) signaling for survival and growth. Therapeutics designed to suppress AR activity serve as the primary intervention for advanced disease. However, supraphysiological androgen (SPA) concentrations can produce paradoxical responses leading to PC growth inhibition. We sought to discern the mechanisms by which SPA inhibits PC and to determine if molecular context associates with anti-tumor activity. SPA produced an AR-mediated, dose-dependent induction of DNA double-strand breaks (DSBs), G0/G1 cell cycle arrest and cellular senescence. SPA repressed genes involved in DNA repair and delayed the restoration of damaged DNA which was augmented by PARP1 inhibition. SPA-induced DSBs were accentuated in BRCA2-deficient PCs, and combining SPA with PARP or DNA-PKcs inhibition further repressed growth. Next-generation sequencing was performed on biospecimens from PC patients receiving SPA as part of ongoing Phase II clinical trials. Patients with mutations in genes mediating homology-directed DNA repair were more likely to exhibit clinical responses to SPA. These results provide a mechanistic rationale for directing SPA therapy to PCs with AR amplification or DNA repair deficiency, and for combining SPA therapy with PARP inhibition.

[1]  A. Chinnaiyan,et al.  Differential modulation of the androgen receptor for prostate cancer therapy depends on the DNA response element , 2020, Nucleic acids research.

[2]  P. Barata,et al.  Evaluation of the genomic alterations in the androgen receptor gene during treatment with high-dose testosterone for metastatic castrate-resistant prostate cancer , 2020, Oncotarget.

[3]  M. Gleave,et al.  Towards precision oncology in advanced prostate cancer , 2019, Nature Reviews Urology.

[4]  U. Testa,et al.  Cellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications , 2019, Medicines.

[5]  J. Isaacs,et al.  Serial bipolar androgen therapy (sBAT) using cyclic supraphysiologic testosterone (STP) to treat metastatic castration-resistant prostate cancer (mCRPC). , 2019, Annals of translational medicine.

[6]  C. Drake,et al.  Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study. , 2018, The Lancet. Oncology.

[7]  Michael D. Nyquist,et al.  Supraphysiologic Testosterone Therapy in the Treatment of Prostate Cancer: Models, Mechanisms and Questions , 2017, Cancers.

[8]  Wiebke Arlt,et al.  Circulating steroid hormone variations throughout different stages of prostate cancer. , 2017, Endocrine-related cancer.

[9]  D. Gerlich,et al.  PARP inhibition causes premature loss of cohesion in cancer cells , 2017, bioRxiv.

[10]  Michael D. Nyquist,et al.  Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling. , 2017, Cancer cell.

[11]  Benjamin P. C. Chen,et al.  Androgen Receptor Variants Mediate DNA Repair after Prostate Cancer Irradiation. , 2017, Cancer research.

[12]  M. Rosenfeld,et al.  Physiological functions of programmed DNA breaks in signal-induced transcription , 2017, Nature Reviews Molecular Cell Biology.

[13]  C. Miranti,et al.  A streamlined method for the design and cloning of shRNAs into an optimized Dox-inducible lentiviral vector , 2017, BMC Biotechnology.

[14]  P. Nelson,et al.  LuCaP Prostate Cancer Patient‐Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease and Serve as Models for Evaluating Cancer Therapeutics , 2017, The Prostate.

[15]  H. He,et al.  Androgen Receptor Tumor Suppressor Function Is Mediated by Recruitment of Retinoblastoma Protein. , 2016, Cell reports.

[16]  M. Porru,et al.  Targeting BRCA1 and BRCA2 Deficiencies with G-Quadruplex-Interacting Compounds , 2016, Molecular cell.

[17]  R. Hales,et al.  Androgen Deprivation Followed by Acute Androgen Stimulation Selectively Sensitizes AR-Positive Prostate Cancer Cells to Ionizing Radiation , 2016, Clinical Cancer Research.

[18]  Hamid Bolouri,et al.  Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer , 2016 .

[19]  Lawrence D. True,et al.  Integrative Clinical Genomics of Advanced Prostate Cancer , 2015, Cell.

[20]  Alan Ashworth,et al.  Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors. , 2015, Annual review of medicine.

[21]  Jun Luo,et al.  Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: Results from a pilot clinical study , 2015, Science Translational Medicine.

[22]  P. Nelson,et al.  DNA damage induces GDNF secretion in the tumor microenvironment with paracrine effects promoting prostate cancer treatment resistance , 2014, Oncotarget.

[23]  S. Jiang,et al.  Androgen Suppresses the Proliferation of Androgen Receptor-Positive Castration-Resistant Prostate Cancer Cells via Inhibition of Cdk2, CyclinA, and Skp2 , 2014, PloS one.

[24]  Neville E. Sanjana,et al.  Improved vectors and genome-wide libraries for CRISPR screening , 2014, Nature Methods.

[25]  Renato Martins,et al.  Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimens. , 2014, The Journal of molecular diagnostics : JMD.

[26]  F. Feng,et al.  A hormone-DNA repair circuit governs the response to genotoxic insult. , 2013, Cancer discovery.

[27]  H. Hieronymus,et al.  Androgen receptor signaling regulates DNA repair in prostate cancers. , 2013, Cancer discovery.

[28]  A. Almasan,et al.  Defective chromatin recruitment and retention of NHEJ core components in human tumor cells expressing a Cyclin E fragment , 2013, Nucleic acids research.

[29]  Karen E. Knudsen,et al.  Ex vivo culture of human prostate tissue and drug development , 2013, Nature Reviews Urology.

[30]  S. Balk,et al.  Androgen Receptor Serine 81 Phosphorylation Mediates Chromatin Binding and Transcriptional Activation* , 2012, The Journal of Biological Chemistry.

[31]  Chih-Pin Chuu,et al.  Androgen suppresses proliferation of castration‐resistant LNCaP 104‐R2 prostate cancer cells through androgen receptor, Skp2, and c‐Myc , 2011, Cancer science.

[32]  John A Tainer,et al.  A structural model for regulation of NHEJ by DNA-PKcs autophosphorylation. , 2010, DNA repair.

[33]  Martin J. Aryee,et al.  Androgen-induced TOP2B mediated double strand breaks and prostate cancer gene rearrangements , 2010, Nature Genetics.

[34]  L. Schwartz,et al.  Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer. , 2009, European urology.

[35]  S. Mohile,et al.  A randomized phase 1 study of testosterone replacement for patients with low-risk castration-resistant prostate cancer. , 2009, European urology.

[36]  Andrei Seluanov,et al.  DNA repair by nonhomologous end joining and homologous recombination during cell cycle in human cells , 2008, Cell cycle.

[37]  M. Benahmed,et al.  Androgen inhibits the growth of carcinoma cell lines established from prostate cancer xenografts that escape androgen treatment , 2008, The Journal of Steroid Biochemistry and Molecular Biology.

[38]  Qi Ding,et al.  trans Autophosphorylation at DNA-Dependent Protein Kinase's Two Major Autophosphorylation Site Clusters Facilitates End Processing but Not End Joining , 2007, Molecular and Cellular Biology.

[39]  David J. Chen,et al.  Ataxia Telangiectasia Mutated (ATM) Is Essential for DNA-PKcs Phosphorylations at the Thr-2609 Cluster upon DNA Double Strand Break* , 2007, Journal of Biological Chemistry.

[40]  M. Rosenfeld,et al.  A Breaking Strategy for Topoisomerase IIβ/PARP-1-Dependent Regulated Transcription , 2006, Cell cycle.

[41]  G. Bubley,et al.  Androgen receptor phosphorylation and stabilization in prostate cancer by cyclin-dependent kinase 1 , 2006, Proceedings of the National Academy of Sciences.

[42]  C. Drake,et al.  Androgen receptor as a licensing factor for DNA replication in androgen-sensitive prostate cancer cells , 2006, Proceedings of the National Academy of Sciences.

[43]  M. Yaffe.  Faculty Opinions recommendation of A topoisomerase IIbeta-mediated dsDNA break required for regulated transcription. , 2006 .

[44]  C. Glass,et al.  A Topoisomerase IIß-Mediated dsDNA Break Required for Regulated Transcription , 2006, Science.

[45]  S. Lees-Miller,et al.  Autophosphorylation of DNA-Dependent Protein Kinase Regulates DNA End Processing and May Also Alter Double-Strand Break Repair Pathway Choice , 2005, Molecular and Cellular Biology.

[46]  H. Scher,et al.  Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  M. Menon,et al.  Synchronized prostate cancer cells for studying androgen regulated events in cell cycle progression from G1 into S phase , 2003, Journal of cellular physiology.

[48]  D. Tindall,et al.  The role of androgens and the androgen receptor in prostate cancer. , 2002, Cancer letters.

[49]  Biaoyang Lin,et al.  The program of androgen-responsive genes in neoplastic prostate epithelium , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[50]  J. Shabanowitz,et al.  Androgen Receptor Phosphorylation , 2002, The Journal of Biological Chemistry.

[51]  Jacques Bernier,et al.  Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial , 2002, The Lancet.

[52]  R. McPherson,et al.  Effect of Long-Term Estrogen Deprivation on Apoptotic Responses of Breast Cancer Cells to 17β-Estradiol , 2001 .

[53]  F. S. French,et al.  Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. , 2001, Cancer research.

[54]  R. McPherson,et al.  Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17beta-estradiol. , 2001, Journal of the National Cancer Institute.

[55]  C. Sonnenschein,et al.  Androgen-induced proliferative quiescence in prostate cancer cells: the role of AS3 as its mediator. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[56]  M. Bosland.  The role of steroid hormones in prostate carcinogenesis. , 2000, Journal of the National Cancer Institute. Monographs.

[57]  N. Hay,et al.  Progression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest. , 1998, Molecular endocrinology.

[58]  M. Piérart,et al.  Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. , 1997, The New England journal of medicine.

[59]  R. Hiipakka,et al.  Human prostate tumor growth in athymic mice: inhibition by androgens and stimulation by finasteride. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[60]  K. Hamil,et al.  Androgen and Glucocorticoid Receptors in the Stroma and Epithelium of Prostatic Hyperplasia and Carcinoma 1 , 2005 .

[61]  H. Klocker,et al.  Androgen receptor status of lymph node metastases from prostate cancer , 1996, The Prostate.

[62]  E. Wilson,et al.  Androgen receptor phosphorylation, turnover, nuclear transport, and transcriptional activation. Specificity for steroids and antihormones. , 1992, The Journal of biological chemistry.

[63]  P. Walsh,et al.  Immunohistochemical study of androgen receptors in metastatic prostate cancer. Comparison of receptor content and response to hormonal therapy , 1991, Cancer.

[64]  E. Nieschlag,et al.  Testosterone: Action, Deficiency, Substitution , 1990 .

[65]  J. Wilson,et al.  Testosterone at high concentrations interacts with the human androgen receptor similarly to dihydrotestosterone. , 1990, Endocrinology.

[66]  A. Traish,et al.  Validation of the exchange assay for the measurement of androgen receptors in human and dog prostates. , 1988, Progress in clinical and biological research.

[67]  R. Sutherland,et al.  Effects of pharmacological concentrations of estrogens on proliferation and cell cycle kinetics of human breast cancer cell lines in vitro. , 1987, Cancer research.

[68]  S. J. Higgins,et al.  The endocrinology and developmental biology of the prostate. , 1987, Endocrine reviews.

[69]  J. Norris,et al.  Mechanism of androgen-receptor augmentation. Analysis of receptor synthesis and degradation by the density-shift technique. , 1985, The Journal of biological chemistry.

[70]  M. Kaufman,et al.  The dissociation of testosterone- and 5 alpha-dihydrotestosterone-receptor complexes formed within cultured human genital skin fibroblasts. , 1983, Journal of steroid biochemistry.

[71]  C. Migeon,et al.  Comparison of methyltrienolone and dihydrotestosterone binding and metabolism in human genital skin fibroblasts. , 1981, Journal of steroid biochemistry.

[72]  P. Walsh,et al.  Characterization of the binding of a potent synthetic androgen, methyltrienolone, to human tissues. , 1978, The Journal of clinical investigation.

[73]  P. Walsh,et al.  The binding of a potent synthetic androgen--methyltrienolone (R 1881)--to cytosol preparations of human prostatic cancer. , 1977, Transactions of the American Association of Genito-Urinary Surgeons.

[74]  F. S. French,et al.  Binding properties of androgen receptors. Evidence for identical receptors in rat testis, epididymis, and prostate. , 1976, The Journal of biological chemistry.

[75]  S. Liao,et al.  Steroid structure and androgenic activity. Specificities involved in the receptor binding and nuclear retention of various androgens. , 1973, The Journal of biological chemistry.